// App-Quantinova.ai

591 : Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.

Researchers

Presenter

  • Christian M. Kurbacher

Principal Investigators

  • Annegret Quade

  • Mathias A. Warm

  • Gerhard KunstmAnn Susanne Herz

  • Jutta A. Kurbacher

Medical Centers

  • Krankenhaus Koln-Holweide, Cologne, Germany

  • Gynecologic Center Bonn-Friedensplatz, Bonn, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved